SecBot SecBot

AUPH

Aurinia Pharmaceuticals Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001600620 Biotech & Drug Discovery
$15.48 −0.25 (−1.59%)
Nov 16 4:00 PM ET · prev $15.73
Market cap
$2.2B
Mid cap
Consensus
Buy
75% Buy or better · 12 analysts
Median target
$18.00
+16% · range $16.00–21.00
1 year
−0.1%
from $15.49 · Nov 17
30 days
−6.1%
from $16.49
52-week range
$13.95–18.62
−17% from high · low Mar 13
Avg volume 20D
922.0K
shares / day
Short interest
7.14M
≈5.3% of shares · −8.3%
Days to cover
10.3
at average volume
Insider net
+$24.6M
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $25.1M at an average $14.66. 1 insider sold $546.4K. Price is 6% above their cost.

  • InstitutionsBULLISH

    Q3 2026: 29 added (0 new), 18 trimmed or exited.

  • AnalystsBULLISH

    9 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.226 → $0.214 over 90 days. 2 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest −8.3% to 7.14M shares. 10.3 days to cover, ≈5.3% of shares.

  • TrendDOWNTREND

    6% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Nuveen, LLCADD1,246,139$20.2M
Qube Research & Technologies LtdDOUBLED989,157$16.0M
FMR LLCADD520,261$8.4M
FEDERATED HERMES, INC.DOUBLED472,057$7.6M
CAPITAL FUND MANAGEMENT S.A.DOUBLED327,554$5.3M
PRINCIPAL FINANCIAL GROUP INCADD251,946$4.1M
FRANKLIN TEMPLETON INCADD204,541$3.5M
Connor, Clark & Lunn Investment Management Ltd.TRIM209,541$3.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 75% rate it Buy or better
Strong Buy3Buy6Hold3Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +16%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 2, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Oct 21, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Aug 7, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform

Insider ledger

Form 4
$25.1M
bought · 1 insider
$546.4K
sold · 1 insider
+5.6%
vs their $14.66 cost
DateInsiderTypeValue
Sep 10, 2026
Robertson Stephen P.
Chief Legal Officer
Sep 10, 2026
SELL$190.4K
Aug 21, 2026
Robertson Stephen P.
Chief Legal Officer
Aug 21, 2026
SELL$355.9K
Jun 4, 2026
Johnson Craig A
Director
Jun 4, 2026
AWARD23,931 sh
Jun 4, 2026
Nova Tina Susan
Director
Jun 4, 2026
AWARD23,931 sh
Jun 4, 2026
Bailey Jeffrey Allen
Director
Jun 4, 2026
AWARD23,931 sh
Jun 4, 2026
Goetz Kathleen
Director
Jun 4, 2026
AWARD23,931 sh
Jun 2, 2026
TANG KEVIN
Chief Executive Officer
Jun 2, 2026
OTHER$16.5K
Jun 2, 2026
TANG KEVIN
Chief Executive Officer
Jun 2, 2026
BUY$3.1M

Earnings setup

Estimates
$0.21
EPS estimate, this quarter
−5%
estimate change, 90 days
2↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.21$0.17–$0.24+7.0%$85.5M
Next Q$0.19$0.17–$0.21+11.8%$83.0M
Current FY$0.97$0.93–$1.00+2.8%$330.1M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
7,137,632
shares short
-8.3%
vs prior settlement
10.3
days to cover
≈5.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 2, 2026 SEC
Three institutional asset managers added to their AUPH positions in Q3 2026, increasing aggregate holdings by $2.2M to…
INST-CLUSTER · Impact 3/10
Oct 30, 2026 SEC
Aurinia Pharmaceuticals reported Q3 2026 total revenue of $83.7M (+14% YoY) and GAAP diluted EPS of $0.23 (flat YoY)…
8-K · Impact 5/10
Oct 30, 2026 Earnings result
AUPH Q3 2026 Earnings: EPS $0.23 (+2.5% vs est)
Sep 30, 2026 Inst.
Nuveen, LLC · ADD
1,246,139 shares ($20.2M)
Sep 30, 2026 Inst.
Qube Research & Technologies · DOUBLED
989,157 shares ($16.0M)
Sep 10, 2026 Insider
Robertson Stephen P. sold 11,939 shares
Chief Legal Officer @ $15.95 ($190.4K)
Aug 25, 2026 Event
LUPKYNIS
WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing malignancies and serious
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

7 filings · 3 bullish · 0 bearish · 1 mixed · 3 neutral
All AUPH filing & press-release reports (7)